Financial Performance - The company reported a revenue of HKD 11,729,000 for the three months ended December 31, 2020, a decrease of 7.7% compared to HKD 12,704,000 for the same period in 2019[3]. - The net profit for the three months ended December 31, 2020, was HKD 1,518,000, compared to a loss of HKD 728,000 in the same period of 2019, indicating a significant turnaround[3]. - For the nine months ended December 31, 2020, the company achieved a revenue of HKD 32,573,000, down from HKD 38,562,000 in the previous year, reflecting a decline of 15.5%[3]. - The basic and diluted earnings per share for the three months ended December 31, 2020, were HKD 0.35, compared to a loss of HKD 0.05 per share in the same period of 2019[3]. - The total comprehensive income for the nine months ended December 31, 2020, was HKD 3,814,000, compared to a loss of HKD 2,199,000 in the same period of 2019[3]. - The group's profit attributable to owners for the nine months ended December 31, 2020, was HKD 3.3 million, a turnaround from a loss of HKD 0.9 million in the same period of 2019[38]. - The basic earnings per share for the nine months ended December 31, 2020, was HKD 0.76, compared to a basic loss per share of HKD 0.19 for the same period in 2019[38]. Revenue Breakdown - Revenue from diagnostic services for the nine months ended December 31, 2020, was HKD 877,000, down 27.6% from HKD 1,213,000 in 2019[15]. - Revenue from prescription and dispensing services for the nine months ended December 31, 2020, was HKD 7,626,000, a decline of 35.5% compared to HKD 11,821,000 in 2019[15]. - The revenue from consultation services, prescription and dispensing services, and treatment services for the nine months ended December 31, 2020, were HKD 0.9 million, HKD 7.6 million, and HKD 24.1 million, accounting for 2.7%, 23.4%, and 73.9% of total revenue respectively[35]. Expenses and Cost Management - The company experienced a significant reduction in employee costs, which amounted to HKD 4,865,000 for the three months ended December 31, 2020, compared to HKD 5,920,000 in the same period of 2019[3]. - Total operating expenses for the nine months ended December 31, 2020, were HKD 5,753,000, down from HKD 7,860,000 in 2019, reflecting a decrease of 26.7%[23]. - Employee costs decreased by HKD 4.3 million or 23.2% to HKD 14.2 million for the nine months ended December 31, 2020, primarily due to a reduction in staff and cost-saving measures[44]. - The group has implemented stricter cost control measures, resulting in a decrease in operating expenses due to reduced variable costs and marketing expenses[36]. Government Support and Compliance - The company has not confirmed any government grants until reasonable assurance is obtained that the conditions will be met[9]. - The company is focused on maintaining compliance with government grant conditions to ensure financial support[9]. - The company received government subsidies totaling HKD 2,285,000 during the nine months ended December 31, 2020, to mitigate the impact of the COVID-19 pandemic[21]. Shareholder Information - As of December 31, 2020, Dr. Jiang held a controlling interest of 68.43% in the company, with 274,865,400 shares registered under Topline Worldwide Limited[52]. - Topline Worldwide Limited, wholly owned by Dr. Jiang, is considered to have a beneficial ownership of 68.43% of the company's shares[56]. - The company repurchased a total of 80,000,000 ordinary shares for a total consideration of HKD 10,000,000, equivalent to HKD 0.125 per share, completed on June 9, 2020[64]. - During the nine months ended December 31, 2020, the company repurchased a total of 4,708,000 ordinary shares at an aggregate cost of HKD 912,000[65]. Governance and Compliance - The company’s board confirmed that the financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and GEM Listing Rules[8]. - The company has adopted the corporate governance code as per GEM Listing Rules and has complied with it during the nine months ended December 31, 2020[60]. - The board believes that the current structure does not undermine the balance of power and authority between the board and the management[61]. - The company has not identified any violations of the trading rules regarding securities transactions by directors during the nine months ended December 31, 2020[63]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited condensed consolidated financial statements for the nine months ended December 31, 2020, and found them compliant with applicable accounting standards and GEM listing rules[69].
密迪斯肌(08307) - 2021 Q3 - 季度财报